{"id":"W4399765099","doi":"10.1200/jco.23.01680","title":"Improved Survival With Adjuvant Cyclooxygenase 2 Inhibition in <i>PIK3CA</i>-Activated Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance)","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Inflammatory mediators and NSAID effects","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hôtel-Dieu de Québec","funders":"National Cancer Institute; National Institutes of Health; Ipsen; Parker Institute for Cancer Immunotherapy; Astellas Pharma; Eisai; Genentech; AstraZeneca; Celgene; FibroGen; Alliance for Clinical Trials in Oncology Foundation; Chugai Pharmaceutical; Agios Pharmaceuticals","keywords":"Medicine; Internal medicine; Hazard ratio; Oncology; Colorectal cancer; Clinical endpoint; Cancer; Celecoxib; Proportional hazards model; Randomized controlled trial; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001203272,0.0003744474,0.0007377993,0.0002464454,0.0001787216,0.000639907,0.0001907262,0.0003466861,0.001606763],"category_scores_gemma":[0.0007127305,0.0001235966,0.001031594,0.000341455,0.0002670478,0.0002768328,0.0002165641,0.0007704481,0.0001535153],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00066526,"about_ca_system_score_gemma":0.001222828,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002681998,"about_ca_topic_score_gemma":0.01128333,"domain_scores_codex":[0.9997563,0.0001110685,0.00001721614,0.00003658294,0.00003305522,0.00004588983],"domain_scores_gemma":[0.9996831,0.00005090711,0.000092717,0.00002627997,0.00003327864,0.0001137329],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6278967,0.00893413,0.02643927,0.00248731,0.00297655,0.0001543688,0.0001361431,0.001689448,0.02849445,0.0003868417,0.01370464,0.2867001],"study_design_scores_gemma":[0.4210373,0.3092058,0.2304247,0.0006270547,0.00730309,0.0005459552,0.0001351126,0.002528989,0.009745921,0.0008607777,0.01751202,0.00007328817],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9870839,0.007302331,0.0002922592,0.0009116604,0.000146505,0.0004677904,0.00110769,0.00005727056,0.002630601],"genre_scores_gemma":[0.9887516,0.004274629,0.0009790432,0.001281743,0.0001871438,0.000430031,0.002529893,0.00001390729,0.001551986],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002681998,"threshold_uncertainty_score":0.006363571,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05588666838383798,"score_gpt":0.4207957034389528,"score_spread":0.3649090350551148,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}